Eli Lilly Multi-Drug Resistant Tuberculosis Partnership

Published 18 Jun 2007
Reference 5435
Region Global
Summary

Once thought eradicated, turbuculosis has infected millions in the last decades throughout Russia, Asia, and Africa, because of its evolving virulence due to inadequate medical delivery. With its TB drugs out of patent, Eli Lilly decided nevertheless to invest $70 million into partnerships to assure that the drug delivery is properly administered. Lilly must now decide whether to increase its commitment to this area which is outside its current drug portfolio.

Teaching objectives

The case has the objective of describing the desperate need of people in the world to be treated properly for curable diseases, and yet the tremendous logistic and organizational problems facing corporations who want to help. The case poses the traditional CSR question of why should a corporation do this, but the primary objective is to analyze strategies that Lilly innovated in order to tackle the vital problem of assuring effective medical delivery of the product.

Keywords
  • RD0507
  • AR2007
  • AR0607